In the latest quarter, 4 analysts provided ratings for Surgery Partners (NASDAQ:SGRY), showcasing a mix of bullish and bearish perspectives.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Surgery Partners, presenting an average target of $40.5, a high estimate of $50.00, and a low estimate of $31.00. Observing a downward trend, the current average is 11.96% lower than the prior average price target of $46.00.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Surgery Partners among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Surgery Partners's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Surgery Partners analyst ratings.

Discovering Surgery Partners: A Closer Look

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.

Surgery Partners's Economic Impact: An Analysis

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Positive Revenue Trend: Examining Surgery Partners's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.69% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Surgery Partners's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1.73%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Surgery Partners's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.63%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Surgery Partners's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.18%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Surgery Partners's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.61.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.